Wall Street analysts expect that China Biologic Products, Inc. (NASDAQ:CBPO) will announce earnings per share (EPS) of $1.36 for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for China Biologic Products’ earnings. China Biologic Products posted earnings per share of $1.10 during the same quarter last year, which would indicate a positive year-over-year growth rate of 23.6%. The business is scheduled to report its next quarterly earnings report on Thursday, August 3rd.

On average, analysts expect that China Biologic Products will report full-year earnings of $4.85 per share for the current year. For the next financial year, analysts forecast that the company will post earnings of $5.95 per share, with EPS estimates ranging from $5.88 to $6.02. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that follow China Biologic Products.

Several brokerages recently issued reports on CBPO. Jefferies Group LLC reiterated a “buy” rating and issued a $140.00 target price on shares of China Biologic Products in a research note on Monday, June 12th. Goldman Sachs Group, Inc. (The) began coverage on shares of China Biologic Products in a research note on Tuesday, May 30th. They issued a “neutral” rating for the company. Zacks Investment Research upgraded shares of China Biologic Products from a “sell” rating to a “buy” rating and set a $121.00 target price for the company in a research note on Tuesday, February 28th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $135.00 target price on shares of China Biologic Products in a research note on Friday, March 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $132.00.

In other China Biologic Products news, insider Zhijing Cbpo Liu sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, May 9th. The shares were sold at an average price of $116.49, for a total transaction of $873,675.00. Following the completion of the sale, the insider now directly owns 10,969 shares in the company, valued at $1,277,778.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 2.73% of the company’s stock.

A number of large investors have recently modified their holdings of the company. FMR LLC increased its stake in shares of China Biologic Products by 27.5% in the first quarter. FMR LLC now owns 1,880,549 shares of the biopharmaceutical company’s stock valued at $188,300,000 after buying an additional 406,105 shares during the period. BlackRock Inc. increased its stake in shares of China Biologic Products by 694.1% in the first quarter. BlackRock Inc. now owns 1,508,096 shares of the biopharmaceutical company’s stock valued at $151,007,000 after buying an additional 1,318,183 shares during the period. FIL Ltd increased its stake in shares of China Biologic Products by 3.2% in the first quarter. FIL Ltd now owns 878,769 shares of the biopharmaceutical company’s stock valued at $87,991,000 after buying an additional 27,493 shares during the period. Hermes Investment Management Ltd. increased its stake in shares of China Biologic Products by 91.6% in the first quarter. Hermes Investment Management Ltd. now owns 631,224 shares of the biopharmaceutical company’s stock valued at $63,204,000 after buying an additional 301,828 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of China Biologic Products by 5.9% in the first quarter. Bank of New York Mellon Corp now owns 563,527 shares of the biopharmaceutical company’s stock valued at $56,426,000 after buying an additional 31,297 shares during the period. Hedge funds and other institutional investors own 74.28% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/06/19/analysts-expect-china-biologic-products-inc-cbpo-will-announce-earnings-of-1-36-per-share.html.

China Biologic Products (NASDAQ CBPO) traded up 0.16% during trading on Monday, hitting $110.52. The company had a trading volume of 146,028 shares. The stock has a 50-day moving average of $113.01 and a 200-day moving average of $109.80. The stock has a market capitalization of $3.01 billion, a PE ratio of 28.62 and a beta of 1.73. China Biologic Products has a one year low of $96.99 and a one year high of $137.38.

About China Biologic Products

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment.

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.